Hyperphosphatemia and Cardiovascular Disease

Area of Science:

• Nephrology
• Cardiology
• Biochemistry

Background:

• Elevated serum phosphate levels, even within the typical laboratory range, are strongly linked to increased cardiovascular disease (CVD) risk and mortality in both the general population and patients with chronic kidney disease (CKD).
• Declining kidney function in CKD leads to rising phosphate levels, which contribute to hypertension, vascular and cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy, and myocardial fibrosis through various mechanisms.

Purpose of the Study:

• To highlight phosphate as a potential therapeutic target for improving cardiovascular outcomes in CKD patients.
• To underscore the need for further research, including large randomized clinical trials, to confirm the causal link between phosphate excess and CVD and to evaluate the efficacy of phosphate-lowering interventions.

Main Methods:

• This study is a review of existing research and clinical observations regarding phosphate metabolism and cardiovascular health in CKD.
• It synthesizes evidence linking hyperphosphatemia to specific cardiovascular pathologies and discusses current management strategies.

Main Results:

• Phosphate excess is a significant risk factor for cardiovascular complications and mortality in CKD.
• Phosphate contributes to CVD development via mechanisms including hypertension, calcification, and cardiac remodeling.

Conclusions:

• Phosphate is a critical therapeutic target for mitigating cardiovascular risk in CKD patients.
• Current strategies focus on dietary and pharmacological phosphate reduction.
• Further large-scale clinical trials are essential to establish causality and therapeutic benefits of lowering serum phosphate for CVD prevention and treatment in CKD.